Two poly (ADP-ribose) polymerase (PARP) inhibitors (olaparib and rucaparib) are US Food and Drug Administration-approved for patients with metastatic castration-resistant prostate cancer (mCRPC) harboring BRCA1/2 mutations, but the relative efficacy of PARP inhibition in BRCA1- versus BRCA2-altered mCRPC is understudied. METHODS: We conducted a multicenter retrospective analysis involving 12 sites. We collected genomic and clinical data from 123 patients with BRCA1/2-altered mCRPC who were treated with PARP inhibitors. The primary efficacy end point was the prostate-specific antigen (PSA) response (≥ 50% PSA decline) rate. Secondary end points were PSA progression-free survival (PSA-PFS), clinical or radiographic PFS, and overall survival. We compared clinical outcomes, and other genomic characteristics, among BRCA1- versus BRCA2-altered mCRPC. RESULTS: A total of 123 patients (13 BRCA1 and 110 BRCA2) were included. PARP inhibitors used were olaparib (n = 116), rucaparib (n = 3), talazoparib (n = 2), and veliparib (n = 2). At diagnosis, 72% of patients had Gleason 8-10 disease. BRCA1 patients were more likely to have metastatic disease at presentation (69% v 37%; P = .04). Age, baseline PSA, metastatic distribution, and types of previous systemic therapies were similar between groups. There were equal proportions of germline mutations (51% v 46%; P = .78) in both groups. BRCA1 patients had more monoallelic (56% v 41%; P = .49) and concurrent TP53 (55% v 36%; P = .32) mutations. PSA50 responses in BRCA1- versus BRCA2-altered patients were 23% versus 63%, respectively (P = .01). BRCA2 patients achieved longer PSA-PFS (HR, 1.94; 95% CI, 0.92 to 4.09; P = .08), PFS (HR, 2.08; 95% CI, 0.99 to 4.40; P = .05), and overall survival (HR, 3.01; 95% CI, 1.32 to 6.83; P = .008). Biallelic (compared with monoallelic) mutations, truncating (compared with missense) mutations, and absence of a concurrent TP53 mutation were associated with PARP inhibitor sensitivity. CONCLUSION: PARP inhibitor efficacy is diminished in BRCA1- versus BRCA2-altered mCRPC. This is not due to an imbalance in germline mutations but might be related to more monoallelic mutations and/or concurrent TP53 alterations in the BRCA1 group.
Two poly (ADP-ribose) polymerase (PARP) inhibitors (olaparib and rucaparib) are US Food and Drug Administration-approved for patients with metastatic castration-resistant prostate cancer (mCRPC) harboring BRCA1/2 mutations, but the relative efficacy of PARP inhibition in BRCA1- versus BRCA2-altered mCRPC is understudied. METHODS: We conducted a multicenter retrospective analysis involving 12 sites. We collected genomic and clinical data from 123 patients with BRCA1/2-altered mCRPC who were treated with PARP inhibitors. The primary efficacy end point was the prostate-specific antigen (PSA) response (≥ 50% PSA decline) rate. Secondary end points were PSA progression-free survival (PSA-PFS), clinical or radiographic PFS, and overall survival. We compared clinical outcomes, and other genomic characteristics, among BRCA1- versus BRCA2-altered mCRPC. RESULTS: A total of 123 patients (13 BRCA1 and 110 BRCA2) were included. PARP inhibitors used were olaparib (n = 116), rucaparib (n = 3), talazoparib (n = 2), and veliparib (n = 2). At diagnosis, 72% of patients had Gleason 8-10 disease. BRCA1 patients were more likely to have metastatic disease at presentation (69% v 37%; P = .04). Age, baseline PSA, metastatic distribution, and types of previous systemic therapies were similar between groups. There were equal proportions of germline mutations (51% v 46%; P = .78) in both groups. BRCA1 patients had more monoallelic (56% v 41%; P = .49) and concurrent TP53 (55% v 36%; P = .32) mutations. PSA50 responses in BRCA1- versus BRCA2-altered patients were 23% versus 63%, respectively (P = .01). BRCA2 patients achieved longer PSA-PFS (HR, 1.94; 95% CI, 0.92 to 4.09; P = .08), PFS (HR, 2.08; 95% CI, 0.99 to 4.40; P = .05), and overall survival (HR, 3.01; 95% CI, 1.32 to 6.83; P = .008). Biallelic (compared with monoallelic) mutations, truncating (compared with missense) mutations, and absence of a concurrent TP53 mutation were associated with PARP inhibitor sensitivity. CONCLUSION: PARP inhibitor efficacy is diminished in BRCA1- versus BRCA2-altered mCRPC. This is not due to an imbalance in germline mutations but might be related to more monoallelic mutations and/or concurrent TP53 alterations in the BRCA1 group.
Authors: Howard I Scher; Michael J Morris; Walter M Stadler; Celestia Higano; Ethan Basch; Karim Fizazi; Emmanuel S Antonarakis; Tomasz M Beer; Michael A Carducci; Kim N Chi; Paul G Corn; Johann S de Bono; Robert Dreicer; Daniel J George; Elisabeth I Heath; Maha Hussain; Wm Kevin Kelly; Glenn Liu; Christopher Logothetis; David Nanus; Mark N Stein; Dana E Rathkopf; Susan F Slovin; Charles J Ryan; Oliver Sartor; Eric J Small; Matthew Raymond Smith; Cora N Sternberg; Mary-Ellen Taplin; George Wilding; Peter S Nelson; Lawrence H Schwartz; Susan Halabi; Philip W Kantoff; Andrew J Armstrong Journal: J Clin Oncol Date: 2016-02-22 Impact factor: 44.544
Authors: Silke Gillessen; Gerhardt Attard; Tomasz M Beer; Himisha Beltran; Anders Bjartell; Alberto Bossi; Alberto Briganti; Rob G Bristow; Kim N Chi; Noel Clarke; Ian D Davis; Johann de Bono; Charles G Drake; Ignacio Duran; Ros Eeles; Eleni Efstathiou; Christopher P Evans; Stefano Fanti; Felix Y Feng; Karim Fizazi; Mark Frydenberg; Martin Gleave; Susan Halabi; Axel Heidenreich; Daniel Heinrich; Celestia Tia S Higano; Michael S Hofman; Maha Hussain; Nicolas James; Ravindran Kanesvaran; Philip Kantoff; Raja B Khauli; Raya Leibowitz; Chris Logothetis; Fernando Maluf; Robin Millman; Alicia K Morgans; Michael J Morris; Nicolas Mottet; Hind Mrabti; Declan G Murphy; Vedang Murthy; William K Oh; Piet Ost; Joe M O'Sullivan; Anwar R Padhani; Chris Parker; Darren M C Poon; Colin C Pritchard; Robert E Reiter; Mack Roach; Mark Rubin; Charles J Ryan; Fred Saad; Juan Pablo Sade; Oliver Sartor; Howard I Scher; Neal Shore; Eric Small; Matthew Smith; Howard Soule; Cora N Sternberg; Thomas Steuber; Hiroyoshi Suzuki; Christopher Sweeney; Matthew R Sydes; Mary-Ellen Taplin; Bertrand Tombal; Levent Türkeri; Inge van Oort; Almudena Zapatero; Aurelius Omlin Journal: Eur Urol Date: 2020-01-27 Impact factor: 20.096
Authors: Matti Annala; Gillian Vandekerkhove; Daniel Khalaf; Sinja Taavitsainen; Kevin Beja; Evan W Warner; Katherine Sunderland; Christian Kollmannsberger; Bernhard J Eigl; Daygen Finch; Conrad D Oja; Joanna Vergidis; Muhammad Zulfiqar; Arun A Azad; Matti Nykter; Martin E Gleave; Alexander W Wyatt; Kim N Chi Journal: Cancer Discov Date: 2018-01-24 Impact factor: 39.397
Authors: Wassim Abida; David Campbell; Akash Patnaik; Jeremy D Shapiro; Brieuc Sautois; Nicholas J Vogelzang; Eric G Voog; Alan H Bryce; Ray McDermott; Francesco Ricci; Julie Rowe; Jingsong Zhang; Josep Maria Piulats; Karim Fizazi; Axel S Merseburger; Celestia S Higano; Laurence E Krieger; Charles J Ryan; Felix Y Feng; Andrew D Simmons; Andrea Loehr; Darrin Despain; Melanie Dowson; Foad Green; Simon P Watkins; Tony Golsorkhi; Simon Chowdhury Journal: Clin Cancer Res Date: 2020-02-21 Impact factor: 12.531
Authors: Wassim Abida; Joanna Cyrta; Glenn Heller; Davide Prandi; Joshua Armenia; Ilsa Coleman; Marcin Cieslik; Matteo Benelli; Dan Robinson; Eliezer M Van Allen; Andrea Sboner; Tarcisio Fedrizzi; Juan Miguel Mosquera; Brian D Robinson; Navonil De Sarkar; Lakshmi P Kunju; Scott Tomlins; Yi Mi Wu; Daniel Nava Rodrigues; Massimo Loda; Anuradha Gopalan; Victor E Reuter; Colin C Pritchard; Joaquin Mateo; Diletta Bianchini; Susana Miranda; Suzanne Carreira; Pasquale Rescigno; Julie Filipenko; Jacob Vinson; Robert B Montgomery; Himisha Beltran; Elisabeth I Heath; Howard I Scher; Philip W Kantoff; Mary-Ellen Taplin; Nikolaus Schultz; Johann S deBono; Francesca Demichelis; Peter S Nelson; Mark A Rubin; Arul M Chinnaiyan; Charles L Sawyers Journal: Proc Natl Acad Sci U S A Date: 2019-05-06 Impact factor: 11.205
Authors: Jon H Chung; Ninad Dewal; Ethan Sokol; Paul Mathew; Robert Whitehead; Sherri Z Millis; Garrett M Frampton; Gennady Bratslavsky; Sumanta K Pal; Richard J Lee; Andrea Necchi; Jeffrey P Gregg; Primo Lara; Emmanuel S Antonarakis; Vincent A Miller; Jeffrey S Ross; Siraj M Ali; Neeraj Agarwal Journal: JCO Precis Oncol Date: 2019-05-10
Authors: Maha Hussain; Joaquin Mateo; Karim Fizazi; Fred Saad; Neal Shore; Shahneen Sandhu; Kim N Chi; Oliver Sartor; Neeraj Agarwal; David Olmos; Antoine Thiery-Vuillemin; Przemyslaw Twardowski; Guilhem Roubaud; Mustafa Özgüroğlu; Jinyu Kang; Joseph Burgents; Christopher Gresty; Claire Corcoran; Carrie A Adelman; Johann de Bono Journal: N Engl J Med Date: 2020-09-20 Impact factor: 91.245
Authors: Michael P Kolinsky; Karen Y Niederhoffer; Edmond M Kwan; Sebastien J Hotte; Zineb Hamilou; Steven M Yip; Kim N Chi; Alexander W Wyatt; Fred Saad Journal: Can Urol Assoc J Date: 2022-04 Impact factor: 2.052